Pentikäinen Olli T, Settimo Luca, Keinänen Kari, Johnson Mark S
Department of Biochemistry and Pharmacy, Abo Akademi University, Tykistökatu 6A, FIN-20520 Turku, Finland.
Biochem Pharmacol. 2003 Dec 15;66(12):2413-25. doi: 10.1016/j.bcp.2003.08.013.
Molecular models were constructed, using the published X-ray structure of rat glutamate receptor 2 (GluR2), for the ligand-binding domains of the human (S)-2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl)propionic acid (AMPA)- and kainate-selective ionotropic glutamate receptors (iGluRs): GluR1-7 and KA1-2. Based on the analysis of the known X-ray structures of GluR2 in complex with glutamate, kainate, and AMPA, we have constructed binding motifs (relative positioning of a ligand in the binding site and the physico-chemical interactions that take place) for selected agonist ligands and found explanations for ligand-binding selectivity to homomeric receptors among the different iGluRs. Even a single sequence difference can explain significant differences in ligand-binding affinities between two receptors. In total, there are seven residues surrounding the binding cavity that affect agonist selectivity: in GluR2, these residues are Pro478, Thr480, Leu650, Ser654, Thr686, Tyr702, and Met708. Each of these seven positions has been shown, or is predicted, to influence the presence of one or more water molecules that, when present, may form bridging hydrogen bonds between particular ligands and receptors. By using this knowledge it should be possible to design new selective agonist ligands with high affinity for any AMPA/kainate receptor.
利用已发表的大鼠谷氨酸受体2(GluR2)的X射线结构,构建了人源(S)-2-氨基-3-(3-羟基-5-甲基-4-异恶唑基)丙酸(AMPA)和红藻氨酸盐选择性离子型谷氨酸受体(iGluR):GluR1-7和KA1-2的配体结合域的分子模型。基于对GluR2与谷氨酸、红藻氨酸盐和AMPA复合物的已知X射线结构的分析,我们构建了选定激动剂配体的结合基序(配体在结合位点的相对定位以及发生的物理化学相互作用),并找到了不同iGluR中配体对同聚体受体结合选择性的解释。即使是单个序列差异也能解释两个受体之间配体结合亲和力的显著差异。总共有七个围绕结合腔的残基影响激动剂选择性:在GluR2中,这些残基是Pro478、Thr480、Leu650、Ser654、Thr686、Tyr702和Met708。这七个位置中的每一个都已被证明或被预测会影响一个或多个水分子的存在,当这些水分子存在时,可能会在特定配体和受体之间形成桥连氢键。利用这些知识,应该有可能设计出对任何AMPA/红藻氨酸盐受体具有高亲和力的新型选择性激动剂配体。